{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:59:28Z","timestamp":1780984768953,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32441090"],"award-info":[{"award-number":["32441090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["No.Z201100005520022"],"award-info":[{"award-number":["No.Z201100005520022"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["23"],"award-info":[{"award-number":["23"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["25-27"],"award-info":[{"award-number":["25-27"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-1-004"],"award-info":[{"award-number":["2022-I2M-1-004"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-2-005"],"award-info":[{"award-number":["2023-I2M-2-005"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-D-001"],"award-info":[{"award-number":["2025-PUMCH-D-001"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-013"],"award-info":[{"award-number":["2022-PUMCH-B-013"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["C-002"],"award-info":[{"award-number":["C-002"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["D-009"],"award-info":[{"award-number":["D-009"]}]},{"name":"the Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2021YFC2501300"],"award-info":[{"award-number":["2021YFC2501300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08105-y","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:29:08Z","timestamp":1776151748000},"page":"3281-3288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib versus BAFF inhibitor in mild to moderate systemic lupus erythematosus: a real-world study based on CSTAR cohort"],"prefix":"10.1007","volume":"45","author":[{"given":"Yutong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2889","authenticated-orcid":false,"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"8105_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW et al (2021) Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17:515\u2013532","journal-title":"Nat Rev Rheumatol"},{"key":"8105_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2478\/rir-2021-0001","volume":"2","author":"M Li","year":"2021","unstructured":"Li M et al (2021) Chinese SLE Treatment and Research Group (CSTAR) Registry 2009-2019: major clinical characteristics of chinese patients with systemic lupus erythematosus. Rheumatol Immunol Res 2:43\u201347","journal-title":"Rheumatol Immunol Res"},{"key":"8105_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2024.04.075","author":"M Li","year":"2024","unstructured":"Li M et al (2024) Incidence and prevalence of systemic lupus erythematosus in urban China, 2013\u20132017: a nationwide population-based study. Sci Bull. https:\/\/doi.org\/10.1016\/j.scib.2024.04.075","journal-title":"Sci Bull"},{"key":"8105_CR4","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288\u2013291","journal-title":"J Rheumatol"},{"key":"8105_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrrheum.2016.137","volume":"12","author":"EE Carter","year":"2016","unstructured":"Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12:605\u2013620","journal-title":"Nat Rev Rheumatol"},{"key":"8105_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2478\/rir-2022-0006","volume":"3","author":"X Tian","year":"2022","unstructured":"Tian X, Li M, Wang Q, Zhao J, Zeng X (2022) The challenges and future perspective for the management of systemic lupus erythematosus in China: a concise annual report of 2020. Rheumatol Immunol Res 3:38\u201344","journal-title":"Rheumatol Immunol Res"},{"key":"8105_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2478\/rir-2020-0009","volume":"1","author":"M Li","year":"2020","unstructured":"Li M et al (2020) 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. Rheumatol Immunol Res 1:5\u201323","journal-title":"Rheumatol Immunol Res"},{"key":"8105_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1515\/rir-2025-0016","volume":"6","author":"J Zhao","year":"2025","unstructured":"Zhao J et al (2025) How will we treat systemic lupus erythematosus in the next 5 years? Rheumatol Immunol Res 6:117\u2013119","journal-title":"Rheumatol Immunol Res"},{"key":"8105_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1515\/rir-2025-0017","volume":"6","author":"J Zhao","year":"2025","unstructured":"Zhao J et al (2025) 2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. Rheumatol Immunol Res 6:120\u2013148","journal-title":"Rheumatol Immunol Res"},{"key":"8105_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay F, Schneider P, Rennert P, Browning J (2003) Baff and april: a tutorial on B cell survival. Annu Rev Immunol 21:231\u2013264","journal-title":"Annu Rev Immunol"},{"key":"8105_CR11","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/ni842","volume":"3","author":"E Claudio","year":"2002","unstructured":"Claudio E, Brown K, Park S, Wang H, Siebenlist U (2002) BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3:958\u2013965","journal-title":"Nat Immunol"},{"key":"8105_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1074-7613(02)00425-9","volume":"17","author":"N Kayagaki","year":"2002","unstructured":"Kayagaki N et al (2002) BAFF\/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17:515\u2013524","journal-title":"Immunity"},{"key":"8105_CR13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/35010115","volume":"404","author":"JA Gross","year":"2000","unstructured":"Gross JA et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995\u2013999","journal-title":"Nature"},{"key":"8105_CR14","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1126\/science.1061964","volume":"293","author":"B Schiemann","year":"2001","unstructured":"Schiemann B et al (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293:2111\u20132114","journal-title":"Science"},{"key":"8105_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","volume":"188","author":"M Hahne","year":"1998","unstructured":"Hahne M et al (1998) April, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188:1185\u20131190","journal-title":"J Exp Med"},{"key":"8105_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721\u2013731","journal-title":"Lancet"},{"key":"8105_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329","journal-title":"Ann Rheum Dis"},{"key":"8105_CR18","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81:1671\u20131675","journal-title":"Drugs"},{"key":"8105_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914413","volume":"24","author":"P Richter","year":"2023","unstructured":"Richter P et al (2023) Cytokines in systemic lupus erythematosus-focus on TNF-\u03b1 and IL-17. Int J Mol Sci 24:14413","journal-title":"Int J Mol Sci"},{"key":"8105_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","volume":"28","author":"CC Mok","year":"2019","unstructured":"Mok CC (2019) The jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs 28:85\u201392","journal-title":"Expert Opin Investig Drugs"},{"key":"8105_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA et al (2021) Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun 12:3391","journal-title":"Nat Commun"},{"key":"8105_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","volume":"78","author":"H You","year":"2019","unstructured":"You H et al (2019) Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis 78:1441\u20131443","journal-title":"Ann Rheum Dis"},{"key":"8105_CR23","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1093\/rheumatology\/keac309","volume":"61","author":"J Yang","year":"2022","unstructured":"Yang J, Li J, Shi L (2022) Successful remission with tofacitinib in a patient with refractory bullous systemic lupus erythematosus. Rheumatology 61:e341\u2013e343","journal-title":"Rheumatology"},{"key":"8105_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdcr.2021.09.030","volume":"20","author":"E Bonnardeaux","year":"2022","unstructured":"Bonnardeaux E, Dutz JP (2022) Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep 20:61\u201364","journal-title":"JAAD Case Rep"},{"key":"8105_CR25","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/ijd.15625","volume":"61","author":"SA Elman","year":"2022","unstructured":"Elman SA, Mazori DR, Merola JF (2022) Tofacitinib for refractory chilblain lupus erythematosus. Int J Dermatol 61:e156\u2013e157","journal-title":"Int J Dermatol"},{"key":"8105_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103440","volume":"22","author":"L Ma","year":"2023","unstructured":"Ma L et al (2023) Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 22:103440","journal-title":"Autoimmun Rev"},{"key":"8105_CR27","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677\u20132686","journal-title":"Arthritis Rheum"},{"key":"8105_CR28","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151\u20131159","journal-title":"Ann Rheum Dis"},{"key":"8105_CR29","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1093\/rheumatology\/keab883","volume":"61","author":"LM Carter","year":"2022","unstructured":"Carter LM et al (2022) Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology (Oxford) 61:4006\u20134015","journal-title":"Rheumatology (Oxford)"},{"key":"8105_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2478\/rir-2023-0023","volume":"4","author":"M Li","year":"2023","unstructured":"Li M et al (2023) Improve quality of patient care for systemic lupus erythematosus in China by enhancing the construction of Centers of Excellence. Rheumatology and Immunology Research 4:162\u2013166","journal-title":"Rheumatology and Immunology Research"},{"key":"8105_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace DJ et al (2014) Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73:183\u2013190","journal-title":"Ann Rheum Dis"},{"key":"8105_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83:475\u2013487","journal-title":"Ann Rheum Dis"},{"key":"8105_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ (2017) Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 18:374\u2013384","journal-title":"Nat Immunol"},{"key":"8105_CR34","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ et al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723\u20131736","journal-title":"N Engl J Med"},{"key":"8105_CR35","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76:1253\u20131262","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08105-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08105-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08105-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:24:37Z","timestamp":1780982677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08105-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8105"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08105-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Peking Union Medical College Hospital Institutional Review Board and Ethical Board (Ethical number: JS-2038). Written informed consent was obtained from each enrolled patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent obtained directly from patient(s).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}